Suppr超能文献

LcrF 是一种耶尔森氏菌属的转录因子,小分子抑制剂能减弱其毒力并限制其在小鼠肺炎模型中的感染。

Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model.

机构信息

Paratek Pharmaceuticals, Inc., Boston, MA 02111, USA.

出版信息

Infect Immun. 2010 Nov;78(11):4683-90. doi: 10.1128/IAI.01305-09. Epub 2010 Sep 7.

Abstract

LcrF (VirF), a transcription factor in the multiple adaptational response (MAR) family, regulates expression of the Yersinia type III secretion system (T3SS). Yersinia pseudotuberculosis lcrF-null mutants showed attenuated virulence in tissue culture and animal models of infection. Targeting of LcrF offers a novel, antivirulence strategy for preventing Yersinia infection. A small molecule library was screened for inhibition of LcrF-DNA binding in an in vitro assay. All of the compounds lacked intrinsic antibacterial activity and did not demonstrate toxicity against mammalian cells. A subset of these compounds inhibited T3SS-dependent cytotoxicity of Y. pseudotuberculosis toward macrophages in vitro. In a murine model of Y. pseudotuberculosis pneumonia, two compounds significantly reduced the bacterial burden in the lungs and afforded a dramatic survival advantage. The MAR family of transcription factors is well conserved, with members playing central roles in pathogenesis across bacterial genera; thus, the inhibitors could have broad applicability.

摘要

LcrF(VirF)是多重适应反应(MAR)家族中的一个转录因子,调节耶尔森氏菌 III 型分泌系统(T3SS)的表达。耶尔森氏菌假结核 lcrF 缺失突变体在组织培养和感染动物模型中表现出毒力减弱。针对 LcrF 的靶向治疗为预防耶尔森氏菌感染提供了一种新的抗毒力策略。在体外测定中,筛选了小分子文库以抑制 LcrF-DNA 结合。所有这些化合物都没有内在的抗菌活性,对哺乳动物细胞也没有表现出毒性。其中一部分化合物抑制了耶尔森氏菌假结核在体外对巨噬细胞的 T3SS 依赖性细胞毒性。在耶尔森氏菌假结核肺炎的小鼠模型中,两种化合物显著降低了肺部的细菌负荷,并提供了显著的生存优势。MAR 家族的转录因子高度保守,其成员在细菌属的发病机制中发挥着核心作用;因此,这些抑制剂可能具有广泛的适用性。

相似文献

3
IscR is essential for yersinia pseudotuberculosis type III secretion and virulence.
PLoS Pathog. 2014 Jun 12;10(6):e1004194. doi: 10.1371/journal.ppat.1004194. eCollection 2014 Jun.
4
Genome Scale Analysis Reveals IscR Directly and Indirectly Regulates Virulence Factor Genes in Pathogenic .
mBio. 2021 Jun 29;12(3):e0063321. doi: 10.1128/mBio.00633-21. Epub 2021 Jun 1.
6
Reduced secretion of YopJ by Yersinia limits in vivo cell death but enhances bacterial virulence.
PLoS Pathog. 2008 May 16;4(5):e1000067. doi: 10.1371/journal.ppat.1000067.
8
Iron availability and oxygen tension regulate the Yersinia Ysc type III secretion system to enable disseminated infection.
PLoS Pathog. 2019 Dec 23;15(12):e1008001. doi: 10.1371/journal.ppat.1008001. eCollection 2019 Dec.
9
Hereditary Hemochromatosis Predisposes Mice to Yersinia pseudotuberculosis Infection Even in the Absence of the Type III Secretion System.
Front Cell Infect Microbiol. 2016 Jun 24;6:69. doi: 10.3389/fcimb.2016.00069. eCollection 2016.
10
YopJ Limits Macrophage Response by Downregulating COX-2-Mediated Biosynthesis of PGE2 in a MAPK/ERK-Dependent Manner.
Microbiol Spectr. 2021 Sep 3;9(1):e0049621. doi: 10.1128/Spectrum.00496-21. Epub 2021 Jul 28.

引用本文的文献

2
Beyond Antibiotics: What the Future Holds.
Antibiotics (Basel). 2024 Sep 25;13(10):919. doi: 10.3390/antibiotics13100919.
4
Pathogenicity and virulence of .
Virulence. 2024 Dec;15(1):2316439. doi: 10.1080/21505594.2024.2316439. Epub 2024 Feb 22.
5
Research Progress on Small Molecular Inhibitors of the Type 3 Secretion System.
Molecules. 2022 Nov 30;27(23):8348. doi: 10.3390/molecules27238348.
6
Antibiotic Therapy of Plague: A Review.
Biomolecules. 2021 May 12;11(5):724. doi: 10.3390/biom11050724.
8
On the road to structure-based development of anti-virulence therapeutics targeting the type III secretion system injectisome.
Medchemcomm. 2019 Jun 20;10(8):1273-1289. doi: 10.1039/c9md00146h. eCollection 2019 Aug 1.
9
A high-throughput system to identify inhibitors of Liberibacter asiaticus transcription regulators.
Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):18009-18014. doi: 10.1073/pnas.1905149116. Epub 2019 Aug 19.
10
The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-Resistant .
Front Microbiol. 2019 Jul 17;10:1557. doi: 10.3389/fmicb.2019.01557. eCollection 2019.

本文引用的文献

2
Targeting type III secretion in Yersinia pestis.
Antimicrob Agents Chemother. 2009 Feb;53(2):385-92. doi: 10.1128/AAC.00670-08. Epub 2008 Nov 17.
3
Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton.
J Bacteriol. 2009 Jan;191(2):563-70. doi: 10.1128/JB.01004-08. Epub 2008 Nov 7.
5
The iron-responsive Fur regulon in Yersinia pestis.
J Bacteriol. 2008 Apr;190(8):3063-75. doi: 10.1128/JB.01910-07. Epub 2008 Feb 15.
7
Inhibitors of type III secretion in Yersinia: design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides.
Bioorg Med Chem. 2007 Nov 15;15(22):6994-7011. doi: 10.1016/j.bmc.2007.07.047. Epub 2007 Aug 22.
8
Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors.
Bioorg Med Chem Lett. 2007 Oct 15;17(20):5652-5. doi: 10.1016/j.bmcl.2007.07.072. Epub 2007 Aug 21.
9
Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors.
Antimicrob Agents Chemother. 2007 Jul;51(7):2631-5. doi: 10.1128/AAC.01492-06. Epub 2007 May 14.
10
Multiple antimicrobial resistance in plague: an emerging public health risk.
PLoS One. 2007 Mar 21;2(3):e309. doi: 10.1371/journal.pone.0000309.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验